Holen Sie sich die Stockscreener-App
5.23
0.95%
-0.05
Handel nachbörslich:
5.23
Schlusskurs vom Vortag:
$5.28
Offen:
$5.25
24-Stunden-Volumen:
231.75K
Relative Volume:
1.12
Marktkapitalisierung:
$226.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-293.42M
KGV:
-0.1951
EPS:
-26.8031
Netto-Cashflow:
$-13.51M
1W Leistung:
-12.40%
1M Leistung:
-12.98%
6M Leistung:
+144.45%
1J Leistung:
+281.75%
1-Tages-Spanne:
$5.02
$5.43
1-Wochen-Bereich:
$5.02
$6.255
52-Wochen-Spanne:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Firmenname
Minerva Neurosciences Inc
Sektor
Branche
Telefon
617-600-7373
Adresse
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
5.23 | 228.49M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-10-02 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-09-01 | Eingeleitet | Citigroup | Buy |
| 2017-03-06 | Fortgesetzt | Jefferies | Buy |
| 2016-05-12 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
NERV Technical Analysis & Stock Price Forecast - Intellectia AI
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Tr - GuruFocus
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Treatment - GuruFocus
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - Stock Titan
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - The Manila Times
No approved drug exists for these schizophrenia symptoms; Minerva starts Phase 3 - Stock Titan
Profit Recap: What is the earnings history of Minerva Neurosciences Inc2026 Bull vs Bear & Detailed Earnings Play Strategies - baoquankhu1.vn
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Guidance Update: Can Minerva Neurosciences Inc stock outperform in a bear market2026 Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8% - MarketBeat
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Minerva Neurosciences : Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia - marketscreener.com
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - MarketBeat
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network
Minerva Neurosciences Presents Data from its Open-label - globenewswire.com
Schizophrenia drug combo showed no safety issues as Phase 3 starts - Stock Titan
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - MarketBeat
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - markets.chroniclejournal.com
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - Stock Titan
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan
Minerva Neurosciences, Inc (NERV) Reports Q4 Earnings - AlphaStreet
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and Statistics - IndexBox
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
BRIEF-Minerva Neurosciences Q4 Net Income USD -283.668 Million - TradingView
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
Finanzdaten der Minerva Neurosciences Inc-Aktie (NERV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):